<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e>) causes increasing morbidity and mortality in haematological <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Reliable cost data for treating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> in German hospitals is not available </plain></SENT>
<SENT sid="2" pm="."><plain>Objective of the study was to determine the institutional cost of treating the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Data were obtained by retrospective chart review in German hospitals </plain></SENT>
<SENT sid="4" pm="."><plain>Patients had either newly diagnosed or relapsed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Direct medical cost was calculated from hospital provider's perspective </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 108 patients were enrolled at 5 tertiary care hospitals, 36 IFD patients and 72 controls </plain></SENT>
<SENT sid="7" pm="."><plain>The vast majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> patients (74%) were diagnosed with invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>On average, the hospital stay for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> patients was 12 days longer than in control patients </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> group and 89% of patients in the control group received <z:chebi fb="0" ids="35718">antifungal drugs</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Mean direct costs per patient were €51,517 in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> group and €30,454 in the control group </plain></SENT>
<SENT sid="11" pm="."><plain>Incremental costs of €21,063 were dominated by cost for <z:chebi fb="0" ids="35718">antifungal drugs</z:chebi> (36%), hospital stay (32%) and blood products (23%) </plain></SENT>
<SENT sid="12" pm="."><plain>From the perspective of hospitals in Germany the economic burden of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is substantial </plain></SENT>
<SENT sid="13" pm="."><plain>Therefore, prevention of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IFD</z:e> is necessary with respect to both clinical and economic reasons </plain></SENT>
</text></document>